Minaris Advanced Therapies, a US-based contract development and manufacturing organisation (CDMO), has unveiled its new manufacturing facility in Munich, Germany.
The new Taufkirchen site enhances Minaris’ global manufacturing network, which includes over 60,000sqm of infrastructure across the US, Europe and Asia. Additionally, it further solidifies Minaris’s role as a reliable partner in the development and commercialisation of advanced therapies.
Go deeper with GlobalData
Minaris’ new facility will facilitate the technology transfer of commercial advanced therapies into Europe. It will consolidate process and analytical development along with legacy manufacturing operations at a single location. Strategically situated near the Munich International Airport, the facility also provides logistical benefits for clients in the region.
The site features six Grade B/A cleanrooms for aseptic manufacturing and one Grade C cleanroom for bioreactors and closed systems. It also offers customizable cleanroom configurations with independently controlled HVAC systems. Additionally, the facility includes dedicated process development and quality control laboratories, cryopreservation and storage facilities, and enhanced alarming and safety systems.
Dr Orla Cloak, chief executive officer of Minaris Advanced Therapies, remarked that the opening of the new facility marked a significant milestone for the company.
“It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability,” she added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMinaris Advanced Therapies is a portfolio company of the US-based investment firm Altaris. It was established by combining two businesses acquired in May 2025. It has around 1,400 employees globally.
